Table 6.

Randomized trials evaluating stereotactic body radiation therapy for localized prostate cancer.

Study	Year	Patient’s Number	PCa Characteristics	Dose (Gy)	ADT	bRFS (Phoenix)		Toxicity
HYPO-RT-PC	2019	589 vs. 591	intermediate (89%) and high (11%) risk	42.7 in 7 f vs. 78.0 in 39 f	-	5 year	84% vs. 84%	2-year grade ≥ 2 GU toxicity	13% vs. 9%	2-year grade ≥ 2 GI toxicity	6% vs. 5%
PACE-B	2022	416 vs. 433	low (8.0%) and intermediate (92.0%) risk	36.25 in 5 f vs. 78 in 39 f or 62 in 20 f	-			2-year grade ≥ 2 GU toxicity	3% vs. 2%	2-year grade ≥ 2 GI toxicity	2% vs. 3%

PCa, prostate cancer; Gy, gray; ADT, androgen deprivation therapy; bRFS, biochemical relapse-free survival; f, fraction; GU, genitourinary; GI, gastrointestinal.